ATE322905T1 - Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten - Google Patents

Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten

Info

Publication number: ATE322905T1
Authority: AT; Austria
Prior art keywords: inhibiting fibrosis; somatostatin agonist; somatostatin; patient; agonist
Prior art date: 1996-08-30

Application number

AT97939392T

Other languages

English (en)

Inventor

Michael D Culler

Philip G Kasprzyk

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-30

Filing date

1997-08-27

Publication date

2006-04-15

1997-08-27 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE322905T1 publication Critical patent/ATE322905T1/de

Links

102000005157 Somatostatin Human genes 0.000 title abstract 3
108010056088 Somatostatin Proteins 0.000 title abstract 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title abstract 3
229960000553 somatostatin Drugs 0.000 title abstract 3
206010016654 Fibrosis Diseases 0.000 title abstract 2
239000000556 agonist Substances 0.000 title abstract 2
230000004761 fibrosis Effects 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Virology (AREA)
Zoology (AREA)
Hematology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)

AT97939392T 1996-08-30 1997-08-27 Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten ATE322905T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US70579096A	1996-08-30	1996-08-30

Publications (1)

Publication Number	Publication Date
ATE322905T1 true ATE322905T1 (de)	2006-04-15

Family

ID=24834961

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT97939392T ATE322905T1 (de)	1996-08-30	1997-08-27	Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten

Country Status (13)

Country	Link
US (3)	US6268342B1 (de)
EP (2)	EP1574219A3 (de)
JP (2)	JP2001500483A (de)
CN (1)	CN1229357A (de)
AT (1)	ATE322905T1 (de)
AU (2)	AU3215597A (de)
CA (1)	CA2264309A1 (de)
DE (1)	DE69735674T2 (de)
ES (1)	ES2258282T3 (de)
HU (1)	HUP9903918A3 (de)
PL (1)	PL331922A1 (de)
WO (2)	WO1998008528A1 (de)
ZA (1)	ZA977783B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998008528A1 (en) *	1996-08-30	1998-03-05	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist
US5968903A (en) *	1998-05-07	1999-10-19	Biomeasure, Incorporated	Inhibition of H. pylori proliferation
IL140837A0 (en) *	1998-07-30	2002-02-10	Sod Conseils Rech Applic	Method of using lanreotide, a somatostatin analogue
EP1291022A1 (de) *	1998-07-30	2003-03-12	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Anwendungsverfahren für lanreotid, ein somatostatin analogon
US6150333A (en) *	1998-07-30	2000-11-21	Biomeasure, Inc.	Methods of using a somatostatin analogue
IES990700A2 (en) *	1999-08-18	2001-08-22	Kinerton Ltd	Process to make a sustained release formulation
WO2001066140A1 (en)	2000-03-09	2001-09-13	Genzyme Corporation	Use of tgf-beta antagonists to treat or to prevent loss of renal function
ES2306766T3 (es)	2001-03-08	2008-11-16	The Administrators Of The Tulane Educational Fund	Antagonistas de somatostatina.
KR20030088494A (ko) *	2001-04-09	2003-11-19	더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드	소마토스타틴 작용제
WO2003016476A2 (en) *	2001-08-14	2003-02-27	Gene Logic, Inc.	Gene expression profiles in glomerular diseases
US20070098784A1 (en)	2001-09-28	2007-05-03	Nutraceutix, Inc.	Delivery system for biological component
US7189856B2 (en) *	2001-12-28	2007-03-13	Gideon Shapiro	Non-peptide somatostatin receptor ligands
WO2004039403A1 (ja) *	2002-10-31	2004-05-13	Senju Pharmaceutical Co., Ltd.	角膜障害治療剤
WO2005007110A2 (en) *	2003-07-11	2005-01-27	Pro-Pharmaceuticals, Inc.	Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) *	2003-09-08	2005-03-10	Eliezer Zomer	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP1522311A1 (de) *	2003-10-10	2005-04-13	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
EP1718146A2 (de) *	2004-02-13	2006-11-08	Pro-Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur behandlung von akne und candida
WO2005082844A1 (en) *	2004-02-27	2005-09-09	Oy Juvantia Pharma Ltd	Treatment of diseases by using a somatostatin receptor agonist
WO2005082845A1 (en) *	2004-02-27	2005-09-09	Oy Juvantia Pharma Ltd	Novel therapies with somatostatin receptor agonists
EP1734970B1 (de)	2004-03-12	2014-12-31	Intercept Pharmaceuticals, Inc.	Behandlung von fibrose mit fxr-liganden
EP1740615B1 (de)	2004-03-31	2014-11-05	Genentech, Inc.	Humanisierte anti-tgf-beta-antikörper
US20080286251A1 (en) *	2004-08-02	2008-11-20	Propharmaceuticals, Inc.	Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
US8454952B2 (en)	2006-03-13	2013-06-04	The Johns Hopkins University	Augmentation of endothelial thromboresistance
WO2008011216A2 (en)	2006-05-16	2008-01-24	Pro-Pharmaceuticals, Inc.	Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
FR2907682B1 (fr) *	2006-10-26	2012-12-07	Vincience	Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
WO2009033730A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratoires Ag	Peptide gxgrgdspca as a therapeutic agent
CN102083451A (zh)	2008-06-12	2011-06-01	赛恩泰新公司	癌症的抑制
CA2727082C (en)	2008-06-12	2019-02-26	Syntaxin Limited	Fusion proteins for use in suppression of acromegaly
GB0820970D0 (en)	2008-11-17	2008-12-24	Syntaxin Ltd	Suppression of cancer
SI2835053T1 (sl)	2010-03-12	2016-09-30	Genzyme Corporation	Kombinirana terapija za zdravljenje raka dojke
WO2011151782A1 (en)	2010-06-02	2011-12-08	Preglem Sa	A role for somatostatin to modulate initiation of follicular growth in the human ovary
EP2399931A1 (de) *	2010-06-22	2011-12-28	Ipsen Pharma S.A.S.	Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
CN103429732B (zh)	2010-12-27	2015-09-16	Lsip基金运营联合公司	iPS细胞及其制造方法
ES2897740T3 (es)	2011-12-28	2022-03-02	Kyoto Prefectural Public Univ Corp	Normalización del cultivo de células endoteliales de la córnea
EP2914276A4 (de)	2012-11-01	2016-07-13	Ipsen Pharma Sas	Somatostatin-analoga und dimere daraus
TWI523863B (zh)	2012-11-01	2016-03-01	艾普森藥品公司	體抑素－多巴胺嵌合體類似物
PT2953948T (pt)	2013-02-07	2017-12-12	Scifluor Life Sciences Inc	Antagonistas de integrina fluorada
US9339515B2 (en)	2013-02-20	2016-05-17	Galectin Therapeutics, Inc.	Method for treatment of pulmonary fibrosis
CA2927898C (en)	2013-10-31	2021-11-16	Kyoto Prefectural Public University Corporation	Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US9790222B2 (en)	2015-02-19	2017-10-17	Scifluor Life Sciences, Inc.	Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
BR112017023432A2 (pt)	2015-04-30	2018-07-24	Scifluor Life Sciences Inc	Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo
WO2016187312A1 (en)	2015-05-18	2016-11-24	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Methods and compositions for treating an alphavirus infection
US10118929B2 (en)	2016-04-27	2018-11-06	Scifluor Life Sciences, Inc.	Nonanoic and decanoic acid derivatives and uses thereof
GB201816637D0 (en) *	2018-10-12	2018-11-28	Heptares Therapeutics Ltd	Selective somatostatin receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4904642A (en) *	1985-09-12	1990-02-27	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
GR862206B (en) *	1985-09-12	1986-12-31	Univ Tulane	Therapeutic somatostatin analogs
US4853371A (en)	1986-06-17	1989-08-01	The Administrators Of The Tulane Educational Fund	Therapeutic somatostatin analogs
GB8716324D0 (en)	1987-07-10	1987-08-19	Sandoz Ltd	Organic compounds
DE3822557C2 (de)	1987-07-10	1998-07-02	Ciba Geigy Ag	Arzneimittel, enthaltend Somatostatine
CA2053250A1 (en)	1989-04-26	1990-10-27	David H. Coy	Linear somatostatin analogs
HU207104B (en)	1991-01-25	1993-03-01	Biosignal Kutato Fejlesztoe Kf	Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
WO1997032604A1 (en) *	1996-03-07	1997-09-12	Novartis Ag	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
WO1998008528A1 (en) *	1996-08-30	1998-03-05	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist

1997
- 1997-05-28 WO PCT/US1997/008999 patent/WO1998008528A1/en not_active Ceased
- 1997-05-28 AU AU32155/97A patent/AU3215597A/en not_active Abandoned
- 1997-08-27 AU AU41490/97A patent/AU726731B2/en not_active Ceased
- 1997-08-27 WO PCT/US1997/014154 patent/WO1998008529A1/en not_active Ceased
- 1997-08-27 PL PL97331922A patent/PL331922A1/xx unknown
- 1997-08-27 ES ES97939392T patent/ES2258282T3/es not_active Expired - Lifetime
- 1997-08-27 AT AT97939392T patent/ATE322905T1/de not_active IP Right Cessation
- 1997-08-27 CA CA002264309A patent/CA2264309A1/en not_active Abandoned
- 1997-08-27 EP EP05076124A patent/EP1574219A3/de not_active Withdrawn
- 1997-08-27 US US09/254,097 patent/US6268342B1/en not_active Expired - Fee Related
- 1997-08-27 JP JP10511678A patent/JP2001500483A/ja active Pending
- 1997-08-27 DE DE69735674T patent/DE69735674T2/de not_active Expired - Lifetime
- 1997-08-27 HU HU9903918A patent/HUP9903918A3/hu unknown
- 1997-08-27 EP EP97939392A patent/EP0938328B1/de not_active Expired - Lifetime
- 1997-08-27 CN CN97197671A patent/CN1229357A/zh active Pending
- 1997-08-29 ZA ZA977783A patent/ZA977783B/xx unknown
2001
- 2001-01-16 US US09/761,605 patent/US6787521B2/en not_active Expired - Fee Related
2004
- 2004-09-07 US US10/935,593 patent/US7238666B2/en not_active Expired - Fee Related
2007
- 2007-10-11 JP JP2007265712A patent/JP2008074857A/ja active Pending

Also Published As

Publication number	Publication date
PL331922A1 (en)	1999-08-16
WO1998008529A1 (en)	1998-03-05
ZA977783B (en)	1999-03-01
EP1574219A2 (de)	2005-09-14
EP1574219A3 (de)	2006-04-26
CN1229357A (zh)	1999-09-22
WO1998008528A1 (en)	1998-03-05
DE69735674T2 (de)	2007-04-05
CA2264309A1 (en)	1998-03-05
EP0938328B1 (de)	2006-04-12
AU726731B2 (en)	2000-11-16
US20050222025A1 (en)	2005-10-06
DE69735674D1 (de)	2006-05-24
AU3215597A (en)	1998-03-19
HUP9903918A3 (en)	2000-07-28
ES2258282T3 (es)	2006-08-16
US7238666B2 (en)	2007-07-03
EP0938328A1 (de)	1999-09-01
HUP9903918A2 (hu)	2000-04-28
US6268342B1 (en)	2001-07-31
JP2001500483A (ja)	2001-01-16
US6787521B2 (en)	2004-09-07
EP0938328A4 (de)	2002-08-28
US20010011072A1 (en)	2001-08-02
AU4149097A (en)	1998-03-19
JP2008074857A (ja)	2008-04-03

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE322905T1 (de)	2006-04-15	Verfahren zur hemmung der fibrose mittels eines somatostatin-agonisten
UA27224C2 (uk)	2000-08-15	Арилалкіламіни, спосіб їх одержання та фармацевтична композиція
EE04911B1 (et)	2007-10-15	Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
NO20003050L (no)	2000-06-14	Metode for Õ administrere monomere insulinanaloger
HUP9902136A3 (en)	2000-03-28	Novel substituted cyclic amino acid derivatives use as pharmaceutical agents
FI20012462A7 (fi)	2002-01-16	Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
BR9503406A (pt)	1996-02-27	Formulaçoes farmacêuticas adaptadas para inhibir para perda de osso em um ser humano
DE69738185D1 (de)	2007-11-15	Verfahren zur Herstellung eines bluddrucksenkenden Mittel enthaltenden ein Dipeptid als wirksames Bestandteil
SE9803760D0 (sv)	1998-11-04	Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EP0981360A4 (de)	2001-05-23	Verfahren zur prevention von gastritis unter verwedund von amylin oder amylin agonisten
DE69837322D1 (de)	2007-04-26	Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
PL350568A1 (en)	2002-12-16	N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60019320D1 (de)	2005-05-12	Verbessertes verfahren zur ermittlung der schleifenkonfiguration eines teilnehmers
MY133169A (en)	2007-10-31	Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
ATE212221T1 (de)	2002-02-15	Verfahren zum herstellen von extrakt enthaltenden pharmazeutischen formulierungen
AU1656997A (en)	1997-10-02	Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
DE69721812D1 (de)	2003-06-12	Verfahren zur herstellung optisch aktiver 3-quinuclidinol derivate
DE60004996D1 (de)	2003-10-09	Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
IL126158A0 (en)	1999-05-09	Method for treating substance abuse
MY124089A (en)	2006-06-30	Use of cetirizine for preventing the onset of asthma
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
DK1011672T3 (da)	2006-02-06	Anvendelse af (E)-metanicotin derivater til frembringelse af analgetiske virkninger
SE9501773D0 (sv)	1995-05-15	New use
EE04951B1 (et)	2008-02-15	R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine unehirete raviks
JO2127B1 (en)	2000-05-21	How to prevent asthma